Compare IDEXX Laboratories, Inc. (IDXX) vs Vanguard Intermediate Term Corporate Bond ETF (VCIT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
IDEXX Laboratories, Inc. vs Vanguard Intermediate Term Corporate Bond ETF — how do they compare? IDEXX Laboratories, Inc. trades at $569.65 (market cap $46.22B), while Vanguard Intermediate Term Corporate Bond ETF trades at $81.19. The key difference: IDEXX Laboratories, Inc. is trading nearer its 52-week high, Vanguard Intermediate Term Corporate Bond ETF nearer its low. Which is the better fit depends on your goals.
| IDXX | VCIT | |
|---|---|---|
Market Cap | $46.22B | — |
Sector | Health | Fixed Income |
52-Week High | $766.68 | $84.82 |
52-Week Low | $526.44 | $81.07 |
Enterprise Value | $47.12B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IDEXX Laboratories (IDXX) trades at $570.58, down 4.23% over 24 hours, with a bullish technical signal and strong fundamentals. The stock has consistently beaten earnings estimates, with Q2 2026 EPS of $4.27 surpassing the $3.94 expectation. Revenue growth remains robust, supported by a 74.21% ROE and expanding diagnostic offerings. Recent news highlights product expansion, including a dual-species cardiac test, reinforcing its market leadership in veterinary diagnostics.
The outlook is positive, driven by durable competitive advantages and international growth potential. However, elevated valuation multiples and competitive pressures pose risks. Analyst consensus is bullish with a $683.33 price target, suggesting significant upside from current levels, though investors should monitor execution on guidance and macroeconomic headwinds.
VCIT, the Vanguard Intermediate-Term Corporate Bond ETF, trades at $81.225 with a modest 0.19% daily gain. Technical indicators show a bearish trend with moving averages signaling sell pressure, though oscillators remain neutral. The ETF maintains consistent monthly dividend distributions, with recent payments of $0.34 and $0.33. Recent financial media coverage highlights VCIT's competitive 0.03% expense ratio and approximately 5% yield compared to similar bond ETFs.
The outlook for VCIT remains balanced with income generation as the primary appeal, though technical weakness suggests near-term pressure. Investment opportunities include attractive yield relative to Treasury alternatives and low expense structure. Risks include interest rate sensitivity and corporate credit quality concerns in changing economic conditions.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About IDEXX Laboratories, Inc.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →About Vanguard Intermediate Term Corporate Bond ETF
VCIT tracks the Bloomberg U.S. 5-10 Year Corporate Bond Index, providing exposure to investment-grade debt from industrial, utility, and financial companies. It acts as a middle-ground bond fund, offering higher yields than short-term bonds with less price volatility than long-term corporate debt.
Read more on VCIT →
